Search

Your search keyword '"Grothey, A."' showing total 3,167 results

Search Constraints

Start Over You searched for: Author "Grothey, A." Remove constraint Author: "Grothey, A."
3,167 results on '"Grothey, A."'

Search Results

2. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

Catalog

Books, media, physical & digital resources

3. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

4. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

6. Incremental cutting-plane method and its application

7. Primal heuristics for Dantzig-Wolfe decomposition for unit commitment

8. Use of Machine Learning Models to Warmstart Column Generation for Unit Commitment

9. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

10. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation

11. The HSV-1 ICP22 protein selectively impairs histone repositioning upon Pol II transcription downstream of genes

12. On the Effectiveness of Sequential Linear Programming for the Pooling Problem

14. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

18. Contributors

19. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study

20. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study

22. Decoding murine cytomegalovirus.

25. Network and Storage

27. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

28. NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

29. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients

31. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines

33. Alternative PV Bus Modelling with the Holomorphic Embedding Load Flow Method

35. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy

36. Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

37. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

39. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

41. Use of Machine Learning Models to Warmstart Column Generation for Unit Commitment.

42. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

45. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma

46. Molecular profile of BRCA-mutated biliary tract cancers

47. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer

48. An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.

49. Genomic analysis of oesophageal carcinoma (EC) to identify recurrent mutations in histone methyltransferases as a distinctive subset.

50. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.